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Abstract
Background: In the fungal pathogen Candida albicans, amino acid substitutions of 14alpha-demethylase (CaErg11p,
CaCYP51) are associated with azole antifungals resistance. This is an area of research which is very dynamic, since the stakes
concern the screening of new antifungals which circumvent resistance. The impact of amino acid substitutions on azole
interaction has been postulated by homology modeling in comparison to the crystal structure of Mycobacterium tuberculosis
(MT-CYP51). Modeling of amino acid residues situated between positions 428 to 459 remains difficult to explain to date,
because they are in a major insertion loop specifically present in fungal species.
Methodology/Principal Finding: Fluconazole resistance of clinical isolates displaying Y447H and V456I novel CaErg11p
substitutions confirmed in vivo in a murine model of disseminated candidiasis. Y447H and V456I implication into fluconazole
resistance was then studied by site-directed mutagenesis of wild-type CaErg11p and by heterogeneously expression into
the Pichia pastoris model. CLSI modified tests showed that V447H and V456I are responsible for an 8-fold increase in
fluconazole MICs of P. pastoris mutants compared to the wild-type controls. Moreover, mutants showed a sustained capacity
for producing ergosterol, even in the presence of fluconazole. Based on these biological results, we are the first to propose a
hybrid homology structure-function model of Ca-CYP51 using 3 different homology modeling programs. The variable
position of the protein insertion loop, using different liganded or non-liganded templates of recently solved CYP51
structures, suggests its inherent flexibility. Mapping of recognized azole-resistant substitutions indicated that the flexibility
of this region is probably enhanced by the relatively high glycine content of the consensus.
Conclusions/Significance: The results highlight the potential role of the insertion loop in azole resistance in the human
pathogen C. albicans. This new data should be taken into consideration for future studies aimed at designing new
antifungal agents, which circumvent azole resistance.
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Introduction
Candida albicans is an opportunistic fungal pathogen that causes
severe blood and disseminated infections (BSIs). The incidence of
these infections has markedly increased over the past decade, due
to the increase of immunocompromised and neutropenic patients
after organ transplantation, cancer therapy or AIDS [1]. In these
populations, C. albicans is associated with a high mortality rate and
the obvious economic consequences [2,3].
Although some antifungal drugs are available (see review [4,5]),
fluconazole (FLC) is still considered the drug of choice to treat
most Candida infections [6–8]. However, long-term exposure to
FLC, as well as FLC underdosage during the empirical regimens,
leads to an increased resistance phenomena [9–16]. Thus, the
understanding of the molecular mechanisms underlying azole
resistance in C. albicans is necessary in order to discover new
antifungal agents that circumvent drug resistance [17,18] and
could guide the choice of the appropriate antifungal treatment at
the onset of infection.
Among the molecular mechanisms involved in the resistance of C.
albicans to azole antifungals we can distinguish the over-expression of
the gene encoding efflux pumps CDR1, CDR2 and MDR1 [19–22]
and/or upregulation or amino acid substitutions of lanosterol 14alpha-
demethylase (CaErg11p, CaCYP51) [11,12,23–26]. CaErg11p partic-
ipates in ergosterol biosynthesis, an essential requirement for yeast
viability [27]. Mutations in the CaErg11 g e n ec a nr e s u l ti na m i n oa c i d
substitutions in the CaErg11p which lead to the decreased affinity of
FLC for its target and can lead to toxic lanosterol accumulation [28].
Among the many CaErg11p substitutions described to date in in vitro
azole-resistant clinical isolates of C. albicans (See review [29]), only a few
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21239of them have been implicated in resistance, using site-directed
mutagenesis [12,30–32]. These mutations are clustered into three
hot spots, ranging from amino acids 105 to 165, 266 to 287 and 405 to
488 [13].
In a previous study, the CaErg11 gene sequencing of 73 C.
albicans clinical isolates displaying various levels of azole suscep-
tibility, allowed us to identify two novel amino acid substitutions,
Y447H and V456I, in two clinical isolates (CAAL61 and CAAL37
respectively) displaying a high-level of FLC resistance (64 mg/ml)
[29]. Although V456I substitution has been previously mentioned
in the literature by Sanglard D and coll. [33], its involvement in
azole resistance has not been investigated so far. Both amino acid
residues located in the third hot spot (amino acid residues 405 to
488) are conserved in various yeast and filamentous fungal species
[29,34]. Whereas, substitutions at these positions could be involved
in azole resistance. However, the interaction of amino acid
residues between positions 428 to 459 with FLC is still difficult to
explain because of a major insertion loop specifically present in
fungal species [35]. To the best of our knowledge, molecular
information of this region is lacking, due to the absence of amino
acid sequence homology between CaErg11p and bacterial- or
trypanosomatid- CYP51 molecular models [34,36–40]. Taken
together, the involvement of both Y447H and V456I substitutions
in FLC resistance remains difficult to solve using the current
homology models of CaCYP51.
Site-directed mutagenesis of the CaErg11 gene and its heterolo-
gous expression in the yeast Saccharomyces cerevisiae is the most
commonly employed model to investigate the potential involvement
of CaErg11p point substitutions on azole resistance [31,41,42].
More recently, Pichia pastoris has emerged as a practical expression
system and is considered a viable alternative to bacterial and S.
cerevisiae expression models [43–45]. Pichia pastoris has also been
suggested as an efficient method for mutant library creation, based
on the selection of single copy plasmid integrated transformants on
low antibiotic concentrations [46]. Furthermore, the P. pastoris
expression model has some advantages such as: (i) the repression of
endogenous genes with low production levels of native proteins, (ii)
the genetic stability of the P. pastoris transformants by gene
integration, (iii) the capacity for eukaryotic post-translational
modifications such as glycosylation and (iv) the possibility of a high
production of mutated recombinant proteins.
In the present study, we introduced single mutations into the
CaErg11 gene by site-directed mutagenesis. We cloned the CaErg11
gene and mutants into P. pastoris to study the contribution of
Y447H and V456I amino acid substitutions in FLC resistance. We
also investigated the effect of these Erg11p substitutions on
ergosterol biosynthesis. Based on the recently published CYP51
ortholog sequence alignments and structures, we first proposed a
hybrid model of CaCYP51 in order to localize amino acid
substitutions in the major insertion loop and to explain their
possible implication on azole resistance.
Results
Azole susceptibility of clinical isolates
Minimal inhibitory concentrations (MICs) of the CAAL37 and
CAAL61 clinical isolates against FLC, ITC and VRC were
determined in vitro (Table 1). The two isolates were resistant for
FLC (MIC =64 mg/ml). The ITR and VRC MICs were changed
in these isolates, although not reaching clinical breakpoints
(CAAL37: 0.125 and 0.06 mg/ml respectively; CAAL61: 0.25 and
0.25 mg/ml respectively). FLC resistance was also confirmed in vivo
in a murine model of disseminated candidiasis. The median survival
of mice groups receiving C. albicans isolates CAAL37, CAAL61
and CAAL97 in the absence of drug treatment, were respectively 2,
3 and 4 days. Virulence of C. albicans was not significantly different
between these drug-free groups (p=0.102 between groups).
Whereas 5 mg/kg of FLC had a significant survival effect on mice
infected by the susceptible CAAL97 isolate (median survival of 13
days after FLC treatment), both CAAL37 and CAAL61 clinical
isolates showed a drastically reduced FLC susceptibility in vivo
(median survival of 3 days). The Kaplan-Meier survival plot clearly
revealed a significant mortality disadvantage of CAAL37 and
CAAL61 isolates after treatment with FLC compared to the
CAAL97 isolate (p=0.02 vs CAAL97) (Figure S1).
Construction of P. pastoris transformants expressing
mutated and wild-type CaErg11p
The general strategy of mutagenesis into P. pastoris is shown in
Figure S2 and Figure S3. A single colony of each P. pastoris mutants,
wild-type and mock controls was used for expression studies in shake
flasks. After one day of cell growth on BMGY medium at 30uC,
250 rpm,the BMGYmedium was then switched to BMMYmedium
containing 0.5% methanol. The yeasts were fed with methanol every
24 h for a period of 96 h. The transformed strain, with the parental
pPIC3.5K plasmid, was used as a control.
SDS-PAGE shows that heterologous expression of the
CaErg11p protein was successfully expressed into P. pastoris. After
Coomassie gel staining, a band of around 56 kDa was detected in
0.5% methanol-induced clones in comparison to the mock control
(Figure 1A). The overall levels of specific intracellular CaErg11p
between P. pastoris mutants and wild-type control are likely to be
relevant after Immunoblot with a polyclonal rabbit anti-Candida
Erg11p analysis compared to the mock control (Figure. 1B). No
band was detected in the induced strain transformed with the
parental plasmid (Mock control). With respect to protein dosage,
CaErg11p expression seems to be lower in Y447H and V456I
mutants than wild-type control under the same experimental
conditions.
Azole susceptibility of P. pastoris CaErg11p transformants
The susceptibility of P. pastoris transformants expressing the wild-
type and mutant CaErg11p proteins to azole compounds was tested
by a microdilution reference method with some modifications. The
K143R substitution was used as resistance-positive control accord-
ing to the site-directed mutagenesis studies showing that this
substitution was responsible of a 64-fold increase of FLC MIC. P.
pastoristransformantscontainingsinglemutations(Y447H,V456Ior
K143R) presented no difference in their MIC to FLC following
growth on a non-inducing medium, BMGY (data not shown).
CaErg11p was then induced in BMMY during 72 h. The
Table 1. Azole antifungal susceptibility and amino acid
substitutions in CaErg11p for the clinical isolates of C.
albicans.
Strain
Site of
isolation MIC (mg/ml)
Amino acid change
in Erg11
FLC ITR VRC
CAAL37 Respiratory
tract
.64 0.125 0.06 E266D, G464S, V456I
h,
V488I
CAAL61 Mouth .64 0.250 0.250 G307S, Y447H
CAAL97 ND 0.120 0.250 0.015 D116E, K128Y
h = heterozygous (i.e., mutation in a single allele).
doi:10.1371/journal.pone.0021239.t001
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modified-reference CLSI test with some modifications. Under these
conditions, methanol was added to 96-well plates every 24 h. These
experiments showed that growth and induction into a BMMY
medium led to a significant increase of FLC MIC (Figure 2A). The
MIC value for P. pastoris transformants containing the Y447H and -
V456I substitutions was 8 mg/ml for FLC, similar to K143R
positive-control mutant. Compared to the wild-type and the
parental plasmid transformants, these values represented an 8-fold
increase in FLC resistance. The MICs to VRC and ITR following
growth and induction into a BMMY medium of P. pastoris
CaErg11p transformants containing single substitutions were
similar, indicating that Y447H and V456I mutations were specific
for the FLC binding to CaErg11p.
The susceptibility of CaErg11p P. pastoris transformants to FLC
was also qualitatively measured by spotting serial dilutions of each
clone on BMMY medium containing various FLC concentrations
(Figure 2B). Under these conditions, 0.5% methanol was added
during CaErg11p pre- induction in BMMY and only at the
beginning of spot tests. The wild-type and mock P. pastoris
transformants were hypersensitive to FLC at 2 mg/ml, whereas the
growth of Y447H, V456I and K143R P. pastoris mutants remained
unchanged (b). After 72 h, P. pastoris mutants showed a better
capacity to growth at high yeast dilution than controls when they
were treated with 4 and 8 mg/ml FLC (c, d).
FLC inhibition of ergosterol biosynthesis in P. pastoris
CaErg11p transformants
The effect of single substitutions on fluconazole resistance was
determined by measuring the catalytic activity of P. pastoris
transformants CaErg11p through the analysis of yeast sterol
composition by gas chromatography-mass spectrometry. The
activity was expressed as the ratio of ergosterol biosynthesis
compared to the toxic lanosterol accumulation (E/L). As expected,
under untreated conditions i.e without FLC (Figure 3A), sterol
composition of wild-type and mock P. pastoris transformants,
showed ergosterol as the dominant sterol (median E/L ratio of 64
for each control). No significant difference was observed for
K143R, Y447H and V456I P. pastoris mutants (median E/L ratio
of 35, 48 and 47, respectively). Under un-treated conditions a
significant difference in E/L ratio was observed between P. pastoris
mutants and wild-type control. The controls and mutants also
showed small quantities of the intermediates of the ergosterol
biosynthesis pathway, such as zymosterol, fecosterol and episterol.
The wild-type, mock and all CaErg11p P. pastoris transformants
were then treated with FLC at two concentrations around their
FLC MICs. Wild-type and mock P. pastoris transformants showed a
marked reduction of sterol 14alpha-demethylase activity after
treatment with FLC (E/L ratio=1) which concords with their
susceptibility to FLC. In contrast, the control mutant K143R
maintained enzymatic activity despite FLC treatment with 4 and
8 mg/ml (median E/L ratio of 9.5 and 5.4, respectively).
Interestingly, demethylation activity of Y447H and V456I mutants
was significantly higher than wild-type control after treatment with
4 mg/ml of FLC as reflected in the E/L ratio of 11.5 and 11
respectively (Figure 3B). When they were treated with 8 mg/ml
FLC, the E/L ratio were also significantly higher than wild-type
control (8.4 for Y447H mutant and 9.3 for V456I) (Figure 3C).
CaCYP51 Insertion loop model and azole-resistant
substitution mapping
CaCYP51 (P10613) was modeled using 3 different homology
modeling programs (Swiss-model, ModWeb and YASARA). All
CaCYP51 structure models, obtained with the different programs,
present the same overall fold typical of CYP51 proteins. The best
model obtained by ModWeb and YASARA used a human
CYP51, respectively ketoconazole (3ld6) and econazole (3jus)
liganded versions presenting 45% sequence identity (residues 49–
525). All the models differ essentially in the position in space of
some connecting loops between alpha-helices of the all alpha-
helical domain of CYP51 and in the position of the large insertion
loop characteristic of fungi phyla CYP51 family members.
ModWeb and YASARA modeled the sequence D428TAAA-
KANSVSFNSSDEVDYGFGKVSKGVSSP459 of CaCYP51 pro-
tein as a long coil pointing out from the protein core (Figure 4A
and 4B). A small sheet, consisting of two small beta-strands, is
located at the tip of the loop in the YASARA model. The last good
Swiss-model represented this loop as a long 2 beta-strands hairpin-
like structure with the DYGFG motif at the top (Figure 4C). This
loop interacts with the alphaB helix and the loop containing the
GGGRHR (alpha-K’’) motif.
Interestingly, one of the two best ModWeb models using the
CYP450 from zebrafish (3b98) represents this insertion with two
small beta-stranded beta-sheet structures that exactly superpose
CaCYP51 Y447 residue over the Y409 residue of the zebrafish
version in close proximity to the catalytically important
G464GGRHRC motif (Figures 4D and S4). Figure 4 localizes
the azole-resistant amino acids positions mapped on the hybrid
models. More than 140 amino acids substitutions of CaCYP51
were reported in literature (reviewed recently by Morio F. and coll.
[29]. Using a criterion of reduced susceptibility isolates and azole-
resistance which have been experimentally proven, we localized
Y132F, Y132H, N136Y, K143R, G307S, S405F, Y447H, G448E,
G448V, G450E and V456I. Three of these positions involved the
substitution of a glycine in a bulkier amino acid, possibly
 
 
 
 
 
 
Figure 1. Expression of recombinant Pichia pastoris transfor-
mants. (A): SDS-polyacrylamide gel electrophoresis analysis. P. pastoris
CaErg11p transformants were induced for protein expression on BMMY
medium for 72 h as described in Material and Methods. Soluble
cytosolic proteins were loaded into a 10% SDS-PAGE gel and stained
with Coomassie brilliant blue. (B): Western blot analysis of control and
mutated CaErg11p proteins produced in P. pastoris. Cytosolic proteins
were transferred to PVDF membranes and incubated with a 1:100
dilution of a polyclonal rabbit anti-yeast Erg11p and a 1:2000 dilution of
goat-anti rabbit-HRP. Signals were visualized using supersignal west
pico substrate detection reagent.
doi:10.1371/journal.pone.0021239.g001
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azole-resistance phenotype due to conformational restriction.
Discussion
The understanding of the molecular mechanisms underlying the
resistance to azole in C. albicans is essential, both in providing
guidance in the selection of the appropriate antifungal agent at the
onset of infection, and in the discovery of new antifungals which
circumvent azole resistance. Intense research in recent years has
highlighted azole resistance as a complex molecular process in
which multiple mechanisms are involved, including overexpression
of the efflux pumps genes [12,20–22] and upregulation or
substitution of the 14alpha-demethylase target enzyme CaErg11p
[11,23,24]. Several of these mechanisms are frequently combined in
a single clinical azole-resistant isolate. Sterol 14alpha-demethylase
Erg11p encoded by the Erg11 gene participates in ergosterol
biosynthesis, a major sterol of the fungal cell membrane that is
required for yeast viability, membrane fluidity and permeability
[27]. From a medical perspective, Erg11p is the primary target of
azole antifungal drugs. The reduction of azole affinity for Erg11p
caused by amino acid substitutions is one of the most frequent
mechanisms involved in azole resistance in C. albicans [28]. In a
previous study, we identified two novel CaErg11p substitutions,
Y447H and V456I possibly involved in azole resistance from two
FLC-resistant (MIC=64 mg/ml) clinical isolates (CAAL61 and
CAAL37, respectively). These isolates presented other CaErg11p
substitutions, G307S for CAAL61, and E266D, G464S, V488I for
CAAL37 [29]. G307S and G464S have been previously identified
in resistant clinical isolates [12]. G464S substitution has been
confirmed to be the cause of FLC resistance in C. albicans due to
reduced affinity for CaErg11p using site-directed mutagenesis [30].
G307S is often associated with other confirmed azole-resistant
substitutions such as G450E and G464S.
In the first part of this study, we aimed to investigate the potential
in vitro contribution of Y447H and V456I CaErg11p substitutions
on FLC resistance. We used site-directed mutagenesis methodology
of the wild-type CaErg11 gene and heterologous expression into P.
pastoris, in order to produce P. pastoris transformants expressing
CaErg11p mutant proteins. We clearly demonstrated that both
Y447H and V456I substitutions were responsible for an 8-fold
increase in FLCMICs determined by a broth microdilutionmethod
when expressed into P. pastoris transformants compared to the wild-
type and parental plasmid controls using CLSI tests. That resistance
levelwasequivalent tothe K143Rpositivecontrol mutant.Next,we
examined the activity of CaErg11p containing single substitutions,
 
 
Figure 2. In vitro antifungal activity of FLC against P. pastoris transformants. (A): P. pastoris cells transformed with WT (%), K143R (&), Y447H
(#) and V456I (N) mutants of CaErg11p were tested according to the CLSI method with some modifications. MIC values were determined as the
lowest antifungal concentration giving a 50% or less reduction in the optical density at 450 nm compared to the OD of the corresponding drug-free
incubation medium. (B): Susceptibilities of CaErg11p P. pastoris transformants to azole fluconazole using spot assay. Serial dilutions of each control
and mutant clones were spotted onto BMMY agar plates containing different concentrations of fluconazole and incubated for 72 h at 30uC.
Untreated conditions (a), 2 mg/ml FLC (b), 4 mg/ml FLC (c) and 8 mg/ml FLC (d).
doi:10.1371/journal.pone.0021239.g002
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before and after FLC treatment. Under un-treated conditions, we
observed a significant difference between wild-type, mock controls
and mutated P. pastoris transformants. This suggests that punctual
mutations (K143R, Y447H and V456I) possibly have an effect on
CaErg11p expression.Thiswouldbeparticularlyrelevantregarding
the lower CaErg11p expression by westernblot compared to
controls. In spite of the lowest ergosterol formation by mutant
clones, these punctual mutations represents, however, an significant
azole resistance advantage when they were treated by FLC
compared to wild-type and mock controls. They showed a sustained
capacity for producing ergosterol even in the presence of FLC. Seen
together, these results clearly highlight the fact that Y447H and
V456I are involved in fluconazole resistance confirming previous
hypotheses with clinical isolates CAAL61 and CAAL37 [29].
Although, Saccharomyces cerevisiae is the most commonly employed
model for studying the role of C. albicans Erg11p substitutions on
azole resistance [31,41,42], we used in this study, the P. pastoris
expression system as an alternative to the expression of mutated
CaErg11p. Importantly, our results using P. pastoris displaying
mutated CaErg11p with a modified broth microdilution method
and sterol biosynthesis experiments, concord with the site-directed
mutagenesis studies into S. cerevisiae. Moreover, P. pastoris has been
proposed as an adapted expression system for mutagenesis studies
[43–45]. Several elements supported these experiments: (i) the use
of methanol inducible AOX1 promoter allows weak expression of
native proteins; (ii) the selection of single copy-gene transformants
avoids the over-expression of mutated proteins; (iii) P. pastoris leads
to the production of post-translational modifications of mutated
proteins such as glycosylation. Fourthly, in the area of directed
evolution of CaErg11p by site-directed mutagenesis, the choice of
an appropriate expression plasmid system is important in order to
express and measure enzyme activity in their natural microsomal
environment. Finally, P. pastoris allows the production and the
Figure 3. CaErg11p activity of P. pastoris transformants in the presence of FLC. P. pastoris CaErg11p methanol-induced
transformants were treated with FLC in BMMY medium for 24 h at 306C. Non-saponifiable lipids (sterols) were extracted as described in
Material and Methods. Sterol identification was done in reference to the relative retention times and mass spectra previously reported [54,55]. Activity
results were expressed as the ratio of ergosterol biosynthesis compared to the lanosterol accumulation (E/L). (A): Untreated P. pastoris clones, (B):
4 mg/ml FLC and (C): 8 mg/ml FLC (n=4).
doi:10.1371/journal.pone.0021239.g003
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and structural analyses by using extracellular expression plasmid
systems.
Because all the fungal CYP51 that have been characterized
were membrane bound microsomal proteins, their crystal
structures have been difficult to resolve to date. The impact of
CaCYP51 substitutions on interaction with azole antifungals was
explained after 3D homology modelling using the amino acid
sequence and the crystal structure of Mycobacterium tuberculosis as a
reference [36–38]. Using this reference, the involvement of
Y447H, V456I and the other amino acid substitutions located at
the fungi-specific insertion sequence is difficult to question. Here,
we proposed, for the first time ever, a novel hybrid model
(YASARA) keeping the general overall core structure of the known
CYP51 ortholog structures as described so far. This model helped
us to map experimentally proved azole-resistant mutants (see
Figure 4). The insertion sequence specifically found in fungal
CYP51 orthologs was modeled as a long coil pointing out from the
surface of the core protein. Because of the absence of homologous
fungal CYP51 crystal structures, the position and interaction of
this loop with the secondary structure core protein is difficult to
model. In each of the 30 models obtained with YASARA, as well
as the two models obtained by ModWeb and the swissmodel, the
variable position of the insertion suggests its inherent flexibility.
The insertion is localized between K’ alpha-helix and the long L
alpha-helix following the conserved catalytic C470 residue.
Moreover, the insertion containing 39 possible positions in the
recently published complete alignment of CYP51 family members
[34] varies greatly in length. Depending on the fungal species, the
insertion varies from 37 amino acid residues (Pichia kudriavzevii)t o
27 amino acids (Schizosaccharomyces pombe). C. albicans CYP51
having a 31 amino acid insertion. The half-N-terminal part of the
insertion is variable in size and in sequence, unlike its half-C-
terminal part which contains a short portion rich in acidic residues
followed by an almost invariable sequence with the motif
DYG[FY]Gx[VI][ST]KG. This motif is not shared with any
protein, although it has a few similarities to a short sequence found
in bacteria GTPase protein EngB.
Using the hybrid model, substitution Y447H is found to be
solvent-accessible and is located in the middle of the invariable
sequence portion of the insertion loop and could possibly modify
the CaCYP51 local structure by disturbing the hydrogen binding
Figure 4. Localization of the major long insertion sequence of CaErg11p and azole-resistance substitutions mapping on CaErg11p
structures obtained by homology modeling. (A): ModWeb model with human CYP51 ketoconazole liganded (3ld6). (B): YASARA model with
human CYP51 liganded with econazole (3jus) with protoporphyrin IX and econazole represented as a stick respectively in orange and yellow. (C):
SwissModel with M. tuberculosis 4-phenylimidazole liganded structure as template (1e9x). (D): ModWeb model zebrafish prostacyclin synthase
CYP450 8a1 free (3b98). All the models are aligned, based on their secondary structure with the N-terminal part of the beta-strand rich domain left
and the alpha-helices rich domain right. The secondary structure of the models are color-coded according to their type, red: beta-stands, blue=
alpha-helices, green= turn, cyan = coil, magenta = the long fungi specific amino acid sequence insertion. Amino acid positions that have been
proven to be responsible for azole-resistance are indicated with the amino acid name of the WT CaCYP51 with yellow for substrate binding site hot-
spots and magenta in the insertion fungi specific sequence. N- and C-terminal are labeled by single letters N and C.
doi:10.1371/journal.pone.0021239.g004
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the mutant, because of the possible environmental dependence
protonation of the H447 nitrogen atom of the azole ring.
Moreover, the modeling of the CaCYP51 insertion sequence with
the structurally similar sequence F389LNADRTEKKDFFKN-
GARVKY409PSVP413 found in zebrafish CYP450 structure
(3b98) position, put the critical Y447 CaCYP51 in a position
superposed over that of the Y409 zebrafish and in direct proximity
to the catalytic important GGGRHRC motif. In contrast, the
V456 position is located in the invariable sequence of the insertion
loop. This position is mutated to isoleucine in almost 50% of the
reported sequences in fungi phyla and could be described as a
polymorphic position.
We note, with interest, that several other substitutions such as
G448E, G448R, G448V, F449S, F449V and F449Y, previously
associated with azole resistance, have been reported in this
insertion region [15,23,24,28,47]. Moreover, protein sequence
alignment of CaCYP51 with other fungal pathogens reveals that
Y447 corresponds to Y431 in Aspergillus fumigatus, a residue
(Y431C) involved in pan-azole resistance in this fungal species
[48]. Looking at these models we could make a hypothesis of a
loop-secondary structure substrate- or an azole-dependent con-
formation transition that could give better substrate availability or
enzyme stability. Moreover, the flexibility of the region is probably
enhanced by the relatively high glycine content occurring in the
consensus sequence. Interestingly, the Y447H mutant is charac-
terized by FLC resistance but remains highly susceptible to
voriconazole which has the best Kd value for the wild-type
CaCYP51 protein [49]. As previously hypothesized for I471T
[49], FLC resistance in the Y447H mutant could be attributed to
reduced affinity for its target.
T h ef a c tt h a ta m i n oa c i d sa tt h ei n s e r t i o nl o o pa r ec o n s e r v e di n
several fungal species, probably indicates their implication in substrate-
azole interaction. Clearer insights into the resistance mechanism of
these mutants could be obtained by in vitro characterization of enzyme
activities using purified wild-type and mutant proteins, recording
circular dichroism and the
1H-NMR spectra of purified proteins in the
presence of substrates/inhibitors in order to look for possible changes in
secondary structure composition and by the elucidation of the C.
albicans CYP51 crystallographic structure.
The construction of a heterologous expression system of
CaErg11p mutants and a molecular model of clinical relevant
amino acid substitutions highlight the potential role of the
CaErg11p insertion loop in azole resistance. The rationale of
preliminary knowledge of the resistance mechanisms before the
design of new azole antifungal candidates, proposed by this
comprehensive investigation, should be taken into consideration
for future studies aimed at designing new azole antifungals against
the human pathogen C. albicans.
Materials and Methods
Cells and vectors
Escherichia coli TOP10F’ (Invitrogen, Inc.) competent cells were
used for the transformation and propagation of recombinant
plasmids. The pBluescript (SK-) (Stratagene GmbH) plasmid was
used for CaErg11 gene cloning and site-directed mutagenesis. The
pPIC3.5K plasmid (Invitrogen) was used for sub-cloning and for
the intracellular expression of CaErg11p protein mutants into the
P. pastoris strain (KM71, aox1::ARG4, Mut
s, His
2). Mut designated
«methanol utilization slow» phenotype was due to the loss of AOX1
gene. The gene coding for CaErg11p was integrated behind the
AOX1 promoter.
Reagents
Restriction enzymes BamHI, NotI, SacI, EcoRI, T4 ligase, calf
intestinal phosphatase (CIP) and DNA molecular weight markers
were purchased from New England Biolabs Inc. Phusion high
fidelity DNA polymerase and buffers came from Finnzymes.
GoTaq Flexi DNA polymerase was from Promega. Agarose was
purchased from Invitrogen.
The NucleoSpin plasmid preparation kit and the NucleoSpin
Extract II DNA fragment extraction kit from agarose gel were
purchased from Macherey-Nagel GmbH. Acid washed beads,
geneticin G418, ampicillin, kanamycin antibiotics, BCA assay
reagents, methanol, n-hexane and glycerol and all oligonucleotide
primers were obtained from Sigma Aldrich Co. Molecular weight
marker for SDS-PAGE, electrophoretic transfer cell for western
blotting and SDS-PAGE equipment were purchased from Biorad.
A polyclonal anti-Candida Erg11p was kindly provided by Dr.
Diane Kelly from the Institute of Life Science, School of
Medecine, Swansea University, Swansea, UK. Anti-rabbit HRP
conjugate was purchased from Cell Signaling Technology Inc.
Super signal West Pico substrate solution was purchased from
Thermo Scientific. FLC was purchased from Sigma, itraconazole
(ITR) from Janssen-Cilag, and voriconazole (VRC) from Sigma
Aldrich Co.
In vitro and in vivo FLC susceptibility of C. albicans clinical
isolates
Antifungal susceptibility to FLC, ITR and VRC was determined
in vitro for CAAL37 and CAAL61 clinical isolates using the broth
microdilution reference method, as recommended by the Clinical
andLaboratoryStandardsInstitute(CLSI)document M27-A2[50].
MIC, that is the lowest drug concentration that resulted in 50%
growth inhibition relative to the growth in the control well, was
visually determined after 48 h of incubation at 35uC.
The In vivo antifungal activity of FLC for the CAAL37 and
CAAL61 clinical isolates was evaluated in a mouse disseminated
candidiasis infection model, according to a previous study [51] with
the following modifications. CAAL97 isolate was used as a FLC
susceptible control. Briefly, four-week-old female Swiss mice
purchased from Elevages Janvier, were housed at the Experimental
Therapy Unit (Faculty of Medicine, Nantes, France). Immunosup-
pression in mice was induced by subcutaneous administration of
prednisolone(30 mg/kg;SigmaAldrichCo)onedaybeforeinfection.
Disseminated candidiasis was induced by intravenous infection with
5610
5 C. albicans cells (CAAL37, CAAL61 and CAAL97 clinical
isolates) in 0.1 ml suspension. Fluconazole (5 mg/kg) was then
administered orally once a day, for 5 days, starting 1 h after infection.
Virulence control groups were inoculated with C. albicans isolates and
were treated with PBS as described above. Survival was monitored
every day, for two weeks after infection. The survival rate was
compared to the control group by using the logrank test and a p value
of less than 0.05 was considered significant.
Culture medium for bacteria and yeast
Luria broth medium supplemented with 100 mg/ml ampicillin
was used for our bacterial culture. 10X YNB: 13.4% yeast
nitrogen base with ammonium sulfate without amino acids. YPD
medium: 1% yeast extract, 2% peptone, 2% dextrose. YPD-
geneticin plates: the same as YPD plus 2% agar and variable
amounts of geneticin. Minimal glycerol medium without histidine
(MGY): 1.34% YNB, 1% glycerol, 4610
25% biotin. Regeneration
dextrose medium without histidine (RD): 1 M sorbitol, 2%
dextrose, 1.34% YNB, 4610
25% biotin, 0.005% amino acids.
RDB plates: the same as RD with 2% agarose. Buffered glycerol-
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100 mM potassium phosphate, pH 6.0, 1.34% YNB, 1% glycerol.
Buffered-methanol complex medium (BMMY): the same as
BMGY with 0.5% methanol replacing glycerol. Breaking buffer:
50 mM sodium phosphate, pH 7.4, 1 mM PMSF, 1 mM EDTA,
5% glycerol.
Isolation and cloning of CaErg11 gene into
pBluescript(SK-)
The CaErg11 gene was isolated from a wild-type C. albicans strain
isolated from the Mycobank of the Parasitology and Medical
Mycology Department, Nantes, FR. The ORFBamHI and ORF-
NotI primers containing a Kozak consensus sequence, were designed
to amplify a 1745 bp cDNA fragment based on the reported
sequence from the GeneBank nucleotide sequencedatabaseaccession
number X13296.1. PCR conditions were as follows: initial
denaturation at 98uC for 5 min, followed by 35 cycles each at
98uCf o r1m i n ,5 8 uCf o r1m i na n d7 2 uCf o r1m i n .F i n a l l yo n e
cycle was performed at 72uC for 10 min.
The CaErg11 gene fragment and pBluescript(SK-) were prepared
for restriction endonuclease digestion with BamHI and NotI. These
primers facilitated the sub-cloning of the coding sequence into
pPIC3.5K. The plasmid (10 mg) and cDNA fragment (1 mg) were
mixed separately with 10 U/mg BamHI, 20 U/mg NotI, 5 ml 10X
BSA, 5 ml 10X NEB3 buffer to a final volume of 50 ml. After
incubation for 1 hour at 37uC, the digests were purified on 1%
agarose gel by using the NucleoSpin Extract II kit (Macherey-
Nagel).Forcloning,20 ngofdigestedpBluescript(SK-)and 60 ngof
CaErg11 cDNA fragment were ligated in 2 ml 10X ligase buffer
(Invitrogen), 1 ml of T4 ligase (2000 U/ml, Invitrogen) and water to
a final volume of 20 ml. The ligation mixture was incubated
overnight at 16uC. Background ligation was determined by self-
ligation of the plasmid and the circular plasmid was used as a
positive control. The recombinant plasmid was named pBSSK-
CaErg11 and electroporated into TOP10F’ E.coli cells.
Site-directed mutagenesis
Site-directed mutagenesis was carried out using a QuikChange
mutagenesis kit (Stratagene). The cloned CaErg11p gene (into
pBlueScript(SK-)) was used as the starting material for constructing
all the mutants. Mutagenic primer sequences for studying Y447H
and V456I substitutions are presented in Table 2. The K143R
substitution was selected as resistance-positive control according to
the site-directed mutagenesis studies published by Chau et al., 2004
[15]. This substitution was responsible of a 64-fold increase of FLC
MIC. Briefly, Phusion DNA polymerase was used to replicate
recombinant plasmid strands with high fidelity. The mutagenic
primers, which were complementary to the opposite strands of
plasmid, were used to induce nucleotide mutations. DpnI endonu-
clease specific for methylated and hemimethylated DNA was used to
digest the parental DNA template and to select for mutation-
containing synthesized DNA. The nicked plasmids were then
transformed into E. coli TOP10F’ competent cells. The full CaErg11
mutant coding region was sequenced using internal primers [52,53].
Construction of recombinant Pichia pastoris
transformants
The general strategy of mutagenesis into P. pastoris is shown in
Figure S2. The CaErg11 gene was isolated from pBlueScript(SK-)
by using BamHI and NotI enzymes and purified after agarose gel
electrophoresis with a NucleoSpin Extract II kit. Purified fragment
was subcloned into the P. pastoris intracellular expression plasmid
pPIC3.5K. The recombinant clones were confirmed through PCR
analysis with ORFBamHI and ORFNotI primers and sequencing
(Figure S3.A).
The recombinant pPIC3.5K-CaErg11 was used to transform P.
pastoris KM71 strain by electroporation. Briefly, 10 mgo f
recombinant plasmids were linearized by 10 U/mg SacI leading
to targeting plasmid for the P. pastoris chromosome at the AOX1
locus. Linearized plasmid were purified from agarose and mixed
with 80 ml competent P. pastoris cells. The mixture was transferred
into an ice-cold 0.2 cm cuvette and an electric shock was given at
2 Kvolts for integration into the P. pastoris genome. Then, 1 M
sorbitol was immediately added. The 0.6 ml of mixture was
poured onto the top of RDB plates and incubated at 30uC until
colonies appeared. The positive transformants that produced
histidine were screened for the ability to grow on YPD-geneticin
plates ranging from 0.25 mg/ml to 2 mg/ml geneticin. The yield
of plasmid transformation was about 3000 colonies per transfor-
mation. Thirty colonies of pPIC3.5K-CaERG11-K143R, 27
colonies of pPIC3.5K-CaERG11-Y447H, 17 colonies of
pPIC3.5K-CaERG11-V456I and 20 colonies of pPIC3.5K-
CaERG11-wild-type were gathered from the YPD-geneticin plates
at the 0.5 and 0.75 mg/ml concentrations, in order to test single-
copy colonies. The His
+Mut
s (methanol utilization slow) transfor-
mants were picked onto RDB plates and resuspended in YPD
containing 15% glycerol and stored at 280uC.
Analysis of P. pastoris recombinant transformants
The geneticin-resistant colonies were also grown in YPD for 24 h,
then the genomic DNA was purified. PCR amplification of the
CaErg11 gene was carried out with 59 AOX1 and 39 AOX primers.
Another PCR analysis was also done using 59AOX1 and a CaErg11
internal R2 primer. The PCR product of recombinant clones was a
band at 1956 bp corresponding to the CaErg11 gene (1745 bp) and a
pieceofpPIC3.5Kplasmid(214 bp)(FigureS3.B).Aband at714 bp
corresponding to a piece of AOX1 promoter (50 bp) and 664 bp of
the 59 extremity of the CaErg11 gene indicates that all P. pastoris
transformants were recombined (Figure S3.C). Recombinant P.
pastoris with the parental plasmid was used as PCR control.
Sequencing analysis
DNA sequencing was performed using an Applied Biosystems 3730
sequencer using internal primers [53]. Nucleotide sequences were
assembled using Seqscape navigator software (Applied Biosystems).
For each mutant, the entire CaErg11 open reading frame sequence
Table 2. Oligonucleotide primers used in this study.
Primer DNA sequence
ORFBamHI 59-GCGGATCCACATATGGCTATTGTTGAAACTG-39
ORFNotI 59-TAGCGGCCGCTTAAAACATACAAGTTTCTCTTTT-39
K143Rfor 59-GGAACAAAGAAAGTTTGCTAAATTTGC-39
K143Rrev 59-GCAAATTTAGCAAACTTTCATTGTTCC-39
Y447Hfor 59-GATGAAGTTGATCATGGGTTTGGG-39
Y447Hrev 59-CCCAAACCCATAGTCAACTTCATC-39
V456Ifor 59-GTTTCTAAAGGGATTTCTTCACC-39
V456Irev 59-GGTGAAGAAATCCCTTTAGAAAC-39
CaCYP51R2 59-AATATAGTTGAGCAAATGAACG-39
59AOX1 59-GACTGGTTCCAATTGACAAGC-39
39AOX1 59-GCAAATGGCATTCTGACATCC-39
doi:10.1371/journal.pone.0021239.t002
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number X13296). The Erg11 sequences of the strains displaying new
amino acid substitutions have been submitted to GenBank database
under accession numbers EU885935 (CAAL37 isolate) and
EU885936 (CAAL61 isolate). An exhaustive list of amino acid
substitutions of each clinical isolate used in this study are presented in
Table 1. The alignment data indicates that Y447H substitution was
homozygous and V456I heterozygous.
Small scale intracellular expression of recombinant
CaErg11p proteins
P. pastoris cells transformed with wild-type, mock, K143R,
Y447H and V456I mutants of the CaErg11p protein were
analyzed for protein expression. Briefly, single colony transfor-
mants from RDB plates were inoculated into 1 ml of BMGY
medium and incubated, whilst being agitated, at 30uC to reach an
absorbance of 2 at 600 nm (18 h), then this 1 ml was inoculated
into 10 ml of BMMY medium at 30uC. Incubation was prolonged
for 96 h with the addition of methanol (0.5% v/v final
concentration) every 24 h. Cells were collected every day by
centrifugation at 3000 g for 10 min and analyzed for the
expression level, protein activity and absorbance at 600 nm.
Western blot analysis
For evaluation of the intracellular accumulation of proteins,
cell pellets were resuspended in 100 ml ice-cold lysis buffer. Cells
were mashed with 100 ml of glass beads (0.2 mm) by doing
several 30 s vortex applications and a cooling cycle. Cell -mashed
slurry was centrifuged at 800 g for 5 min at 4uC. The collected
supernatants (soluble cytosolic proteins), were centrifuged at
13000 g for 10 min at 4uC. The protein content of clear
supernatant was quantified using BCA assay. Forty mgp r o t e i n
per well were loaded into 10% SDS-PAGE gels. Electrophoresis
was performed according to the Laemmli method. After
electrophoresis, the gels were stained with Coomassie brillant
blue R-250 and distained with a mixture of acetic acid-methanol-
water (10:25:65 v/v). Proteins were also transferred to PVDF
membranes and incubated with a 1:100 dilution of polyclonal
anti-Candida Erg11p produced in rabbit overnight at 4uCa n da
1:2000 dilution of goat-anti rabbit antibody coupled to HRP 1 h
at room temperature. The signals were visualized using the super
signal west pico substrate detection reagent.
Azole susceptibility tests for P. pastoris transformants
The susceptibility of P. pastoris transformants expressing the
wild-type and mutant CaErg11p proteins to azole compounds
was tested using two methods. First, a broth microdilution
reference method, as recommended by the Clinical and
Laboratory Standards Institute (CLSI) document M27-A2 [50].
In some experiments RPMI1640 medium, which is usually used
in this method, was replaced by BMMY liquid medium. A final
concentration of 0.5% methanol at was added every 24 h to
each well in order to guarantee protein induction. The MIC was
defined as the antifungal concentration giving a 50% or less
reduction in the optical density at 450 nm compared to the OD
of the corresponding drug-free incubation medium. Secondly, a
qualitative test was carried out by spotting serial dilutions of
induced yeast onto agar plates containing BMMY medium. The
azole compounds were diluted at different concentrations into
BMMY plates. The P. pastoris transformants were induced at
30uC for 72 h in BMMY liquid medium and diluted to 2610
7
cells per ml in 0.9% NaCl. Five microliters of this suspension
and 5 ml of serial dilutions of each yeast culture were spotted
onto each type of plate. The plates were incubated for 72 h and
96 h at 30uC.
FLC effect on ergosterol biosynthesis by P. pastoris
CaErg11p transformants
After P. pastoris CaErg11p induction for 72 h at 30uC in BMMY
medium, yeast cells were harvested and treated with various
concentrations of FLC in BMMY medium for 24 h at 30uC. The
treated cells were then harvested and resuspended in 3 ml of 60%
(wt/v) KOH and saponified by heating at 80uC for 2 h. Non
saponifiable lipids (sterols) were extracted from the saponified
mixture, twice, with 2 ml of n-hexane pooled, and dried under
nitrogen. The sterols were suspended in 100 ml of bis(trimethylsilyl)
trifluoride for 30 min for silylation. The silyled sterols were
analyzed by gas chromatography-mass spectrometry (Agilent
Technologies). The sterol identification was done in reference to
the relative retention times and mass spectra previously reported
[54,55] (n=4).
CaCYP51 homology modeling
CaCYP51 (P10613) was modeled using 3 different homology
modeling programs. The Swiss-model repository already contains
a CaCYP51 model using Mycobacterium tuberculosis 4-phenylimida-
zole liganded structure as a template (1e9x). 2 homology models
were retrieved from the server version of modeler (ModWeb) with
human CYP51 ketoconazole liganded (3ld6) and zebrafish
prostacyclin synthase CYP450 8a1 free (3b98) as templates.
Finally, the homology modeling module of the YASARA program
(www.yasara.org) [56] using the latest CYP51 crystallographic
structures that have been resolved, was used. YASARA homology
modeling uses 6 different crystallographic structures as templates
from different phyla, M. tuberculosis liganded (2w0b and 2w0a),
human econazole liganded (2jus) and T. brucei liganded (3gw9) and
free (3g1q), T. cruzi liganded (2wx2) selected automatically by PSI-
BLAST optimized sequence alignments with the target sequence.
After secondary structure prediction, loop construction and amino
acid rotamers selection, molecular dynamic steps were performed
with the YASARA default force field parameters and the 6
energetically lowest structures per template were retained after
stereochemistry validation. A total of 30 models were then scored,
sorted by Z-score and a unique hybrid model consisting of the best
part of the 30 models was obtained. This hybrid model was
submitted to a final molecular dynamics round and its quality
evaluated and retained if its pertinence had improved. The effects
of Y447H and V456I mutations at a molecular level were then
further analyzed using the Foldx plugin within the program
YASARA.
Ethics Statement
This study was carried out in strict accordance with the
recommendations of the Directive 86/609/EEC on the protection
of animals used for experimentals and other scientific purposes.
The protocol was approved by the Committee on Ethics of Animal
Experiments of the Experimental Therapy Unit (UTE) of the
Faculty of Medicine, University of Nantes, France (C-44015). The
mice were anesthetized by inhalation of an isoflurane-air mix (2%,
1 l/min) before any manipulation and all efforts were made to
minimize suffering.
Supporting Information
Figure S1 FLC susceptibility of clinical isolates. The In vivo
antifungal activity of FLC against the clinical isolates was evaluated
in a mouse disseminated candidiasis infection model. Briefly,
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subcutaneous administration of prednisolone (30 mg/kg) one day
before infection. Disseminated candidiasis was induced by intrave-
nous infection with 5610
5 C. albicans cells. After 1 h after infection,
mice were treated either with PBS or FLC (5 mg/kg) orally once a
day, for 5 days. Survival was monitored every day, for two weeks
after infection. The survival rate was compared to the control group
by using the logrank test and a p value of less than 0.05 was
considered significant. CAAL37 (&), CAAL37+ FLC (%),
CAAL61 (m), CAAL61+ FLC (n), CAAL97 (N) and CAAL97+
FLC (#).
(EPS)
Figure S2 Outline of a strategy for cloning wild-ype and
mutated CaErg11 genes from C. albicans isolates and for predicting
alterations of CaErg11p.
(EPS)
Figure S3 Construction of recombinant Pichia pastoris transfor-
mants. (A): Integration of CaErg11 mutant genes into mutagenesis
pBSSK(-) plasmid confirmed by PCR using ORFBamHI and
ORFNotI primers. Lane 1: pBSSK-CaErg11-K143R, lane 2:
pBSSK-CaErg11-Y447H, lane 3: pBSSK-CaErg11-V456I, lane 4:
pBSSK-CaErg11-wild-type and lane 5: PCR of pBSSK(-) mock
control. (B): The genomic DNA from representative P. pastoris
transformants was purified. PCR amplification of the CaErg11
gene with 59 AOX1 and 39 AOX primers. (C): PCR amplification
of the CaErg11 gene with 59AOX1 and a CaErg11p internal R2
primer. Lane 1: CaErg11-K143R, lane 2: CaErg11-Y447H, lane
3: CaErg11-V456I, lane 4: CaErg11-wild-type and lane 5: PCR of
pPIC3.5K transformed P. pastoris.
(EPS)
Figure S4 ModWeb model of CaCYP51 (P10613) with zebrafish
prostacyclin synthase CYP450 8a1 free (3b98) as template. The
long fungi specific loop is represented in magenta. Mapped are the
amino acid substitutions Y447H, G448E, G450E and V456I.
(EPS)
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